Monday, July 14

• Novellus Systems Inc. (NASDAQ: NVLS) to report Q2 earnings; conference call at 4:30 pm.
• Genentech Inc. (NYSE: DNA) to report Q2 earnings; conference call at 4:45 pm.

Tuesday, July 15

• PDUFA date for Sciele Pharma, Inc. (SCRX)'s NDA for Aquelle for the treatment of head lice by asphyxiation.
• Johnson & Johnson (NYSE: JNJ) to report Q3 earnings; conference call at 8:30 am.
• Senate Finance Committee: International Enforcement of Intellectual Property Rights meeting at 10:00 am with Sony Corp. (NYSE: SNE) and Pfizer Inc. (NYSE: PFE) appearing.

Sciele Pharma (NASDAQ: SCRX) announced the FDA approved its new formulation of Sular (high blood pressure treatment).

SCRX closed at $19.84 Wednesday.

Friedman BIlings says: "Successful execution of the Sular switch will remain a concern for investors and depress the near-term share valuation."

SCRX January option implied volatility of 82 is above its 26-week average of 48 according to Track Data, suggesting larger risk.

Options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com